SCHEMBL4290310

SCHEMBL4290310

Brc1ccc2[nH]nc(-c3nccs3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.56
CLK4 Q9HAZ1 3/20 0.56
PRKD3 O94806 2/20 0.56
MAP4K4 O95819 2/20 0.56
CSF1R P07333 2/20 0.56
CLK2 P49760 2/20 0.56
MAP4K2 Q12851 2/20 0.56
DYRK1A Q13627 2/20 0.56
NTRK3 Q16288 2/20 0.56
AURKB Q96GD4 2/20 0.56
DCLK1 O15075 1/20 0.56
CHEK2 O96017 1/20 0.56
FER P16591 1/20 0.56
CDK2 P24941 1/20 0.56
MARK3 P27448 1/20 0.56
FLT4 P35916 1/20 0.56
MAPK9 P45984 1/20 0.56
CSNK1D P48730 1/20 0.56
CSNK2A1 P68400 1/20 0.56
CSNK1G2 P78368 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5388742 0.80 LRRK2 (0.54) PDPK1ADORA2AADORA1CDC7HTR2A
SCHEMBL4291869 0.76 FLT3 (0.60) FLT3CLK4PRKD3MAP4K4CSF1R
SCHEMBL5429209 0.75 CLK1 (0.52) CSNK1DCSNK2A1CSNK1G2PDPK1HTR2A
SCHEMBL2660635 0.74 GRM4 (0.58) FLT3CLK4PRKD3MAP4K4CSF1R
SCHEMBL2731639 0.72 FLT3 (0.75) FLT3CLK4PRKD3MAP4K4CSF1R
SCHEMBL4316858 0.72 DCLK1 (1.00) FLT3CLK4PRKD3MAP4K4CSF1R
SCHEMBL12500458 0.72 GRM4 (0.55) FLT3AURKBCDK2PDPK1ADORA2A
SCHEMBL3705844 0.71 TTK (0.55) PDPK1ADORA2AADORA1CDC7FGFR1
SCHEMBL16025493 0.71 FLT3 (0.62) FLT3CLK4PRKD3MAP4K4CSF1R
SCHEMBL26204516 0.71 FLT3 (0.50) FLT3CLK4PRKD3MAP4K4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885CLK4 260/4885PRKD3 75/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885CLK4 260/4885PRKD3 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.